News by Subject
News by Disease
News by Date
Post Your News
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
US & Canada
Post an Event
News | News By Subject | News by Disease |
News By Date | Search News
Islet Sciences Triple-Threat Against Diabetes Would Alter the Landscape in Treatment
6/24/2013 9:07:28 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
CHICAGO, IL, June 22, 2013 – Early detection, immunotherapy and Islet cell transplantation could be the first real hope in decades for insulin-dependent diabetics seeking relief from the grueling daily regimen of insulin injections, glucose monitoring and what has been considered irreversible damage to organs, nerves and the vascular system, according to research being presented this weekend at the American Diabetes Association’s 73rd Scientific Sessions in Chicago.
Islet Sciences CEO John Steel says they have a three-pronged approach to the prevention, treatment and damage-reversal of diabetes.
“Early diagnosis is key – it’s the beginning of what we do,” says Steel, himself a diabetic. “Islet Sciences uses DNA technology to diagnose insulin-dependent diabetes years before cell damage even occurs.”
Steel says that type of warning system can save millions of lives.
Link to article here: (The latest findings of Islet Science’s research into early detection and advanced insulin-producing cell transplantation is highlighted in the following news article.)
Also being presented in Chicago is data that gives realistic hope that insulin producing cells can be effectively transplanted into patients.
Dr. Jonathan Lakey, PhD, MSM, the Chief Scientific Officer of Islet Sciences, says, “There’s existing clinical evidence that if you put islet replacement therapy into a human who’s had diabetes for some time, you reverse many of the comorbid indications, such as neuropathy and retinopathy. We want to alter the landscape in the treatment of Insulin-dependent diabetes.”
The research could allow insulin-dependent diabetics to forego daily insulin injections for years at a time.
According to Islet Sciences, the company will use Islet Sciences-P, a ready-to-use suspension of microencapsulated porcine islets for injection into the abdominal cavity. The company plans to move the technology into human studies later next year, beginning in the U.S.
Islet Sciences would then use the technology once approved by the FDA.
About Islet Sciences, Inc.
Islet Sciences is a development-stage biotechnology company with patented technologies focused on infusion therapy for people with insulin-dependent diabetes. The Company's infusion technology includes methods for the culturing, isolation, maturation, and immunoprotection (microencapsulation) of islet cells. The Company's mission includes the introduction of commercial products relevant to the insulin dependent diabetes marketplace including diagnostics and anti inflammatory compounds. For more information: www.isletsciences.com
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements for Islet Sciences reflect current expectations, as of the date of this press release, and involve certain risks and uncertainties. Actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the risks described in the Islet Science's reports filed with the Securities and Exchange Commission. The companies' further development is highly dependent on future medical and research developments and market acceptance, which is outside their control.
Help employers find you! Check out all the jobs and post your resume.